相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Discharge status validation of the Chang Gung Research database in Taiwan
Yu-Tung Huang et al.
BIOMEDICAL JOURNAL (2022)
Kidney Function Change and All-Cause Mortality in Denosumab Users with and without Chronic Kidney Disease
Ping-Hsun Wu et al.
JOURNAL OF PERSONALIZED MEDICINE (2022)
The Global Burden of Osteoporosis, Low Bone Mass, and Its Related Fracture in 204 Countries and Territories, 1990-2019
Yuyan Shen et al.
FRONTIERS IN ENDOCRINOLOGY (2022)
Denosumab Recovers Aortic Arch Calcification During Long-Term Hemodialysis
Shunji Suzuki et al.
KIDNEY INTERNATIONAL REPORTS (2021)
Alleviation of Inflammation and Oxidative Stress in Pressure Overload-Induced Cardiac Remodeling and Heart Failure via IL-6/STAT3 Inhibition by Raloxifene
Shengqi Huo et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2021)
Raloxifene has favorable effects on the lipid profile in women explaining its beneficial effect on cardiovascular risk: A meta-analysis of randomized controlled trials
Fang Yang et al.
PHARMACOLOGICAL RESEARCH (2021)
The Effect of Raloxifene Treatment on Lipid Profile in Elderly Individuals: A Systematic Review and Meta-analysis of Randomized Clinical Trials
Hong Shi et al.
CLINICAL THERAPEUTICS (2021)
Postmenopausal Osteoporosis: Latest Guidelines
Rod Marianne Arceo-Mendoza et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2021)
Characterizing Multimorbidity from Type 2 Diabetes Insights from Clustering Approaches
Meryem Cicek et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2021)
Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society
Jennifer Blake et al.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY (2021)
Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update
Dolores Shoback et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Impact of denosumab on cardiovascular calcification in patients with secondary hyperparathyroidism undergoing dialysis: a pilot study
C-L Chen et al.
OSTEOPOROSIS INTERNATIONAL (2020)
RANKL biology: bone metabolism, the immune system, and beyond
Takehito Ono et al.
INFLAMMATION AND REGENERATION (2020)
Comparison of the Effects of Denosumab and Alendronate on Cardiovascular and Renal Outcomes in Osteoporotic Patients
Tsuen-Wei Hsu et al.
JOURNAL OF CLINICAL MEDICINE (2019)
The Paradoxical Role of Uric Acid in Osteoporosis
Kun-Mo Lin et al.
NUTRIENTS (2019)
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2019)
The Chang Gung Research Database-A multi-institutional electronic medical records database for real-world epidemiological studies in Taiwan
Shih-Chieh Shao et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2019)
Economic burden of stroke: a systematic review on post-stroke care
S. Rajsic et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2019)
The Tumor Necrosis Factor Superfamily Member RANKL Suppresses Effector Cytokine Production in Group 3 Innate Lymphoid Cells
Jennifer K. Bando et al.
IMMUNITY (2018)
The Number of Comorbidities Predicts Renal Outcomes in Patients with Stage 3-5 Chronic Kidney Disease
Wen-Chin Lee et al.
JOURNAL OF CLINICAL MEDICINE (2018)
Association of Multimorbidity with Mortality and Healthcare Utilization in Chronic Kidney Disease
C. Barrett Bowling et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2017)
DJ-1 controls bone homeostasis through the regulation of osteoclast differentiation
Hyuk Soon Kim et al.
NATURE COMMUNICATIONS (2017)
Multimorbidity in people with chronic kidney disease: implications for outcomes and treatment
Simon D. S. Fraser et al.
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2016)
Vascular calcification in type-2 diabetes and cardiovascular disease: Integrative roles for OPG, RANKL and TRAIL
Emma Harper et al.
VASCULAR PHARMACOLOGY (2016)
Osteoporosis and cardiovascular disease: an update
S. Lello et al.
GYNECOLOGICAL ENDOCRINOLOGY (2015)
Inhibition of the TNF Family Cytokine RANKL Prevents Autoimmune Inflammation in the Central Nervous System
Matteo M. Guerrini et al.
IMMUNITY (2015)
RANKL Inhibition With Denosumab Does Not Influence 3-Year Progression of Aortic Calcification or Incidence of Adverse Cardiovascular Events in Postmenopausal Women With Osteoporosis and High Cardiovascular Risk
Elizabeth J. Samelson et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2014)
The use of raloxifene in osteoporosis treatment
Patrizia D'Amelio et al.
EXPERT OPINION ON PHARMACOTHERAPY (2013)
Inhibition of Receptor Activator of NF-κB Ligand by Denosumab Attenuates Vascular Calcium Deposition in Mice
Susann Helas et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research
Peter C. Austin
COMMUNICATIONS IN STATISTICS-SIMULATION AND COMPUTATION (2009)
Antifracture Efficacy and Reduction of Mortality in Relation to Timing of the First Dose of Zoledronic Acid After Hip Fracture
Erik Fink Eriksen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Central control of fever and female body temperature by RANKL/RANK
Reiko Hanada et al.
NATURE (2009)
Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: A key mechanism in osteoporosis
Patrizia D'Amelio et al.
BONE (2008)
Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice
Sean Morony et al.
CIRCULATION (2008)
Transmenopausal changes in the trabecular bone structure
M. P. Akhter et al.
BONE (2007)
Vascular calcification and osteoporosis-from clinical observation towards molecular understanding
L. C. Hofbauer et al.
OSTEOPOROSIS INTERNATIONAL (2007)
Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells
Karin Loser et al.
NATURE MEDICINE (2006)
Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women
Elizabeth Barrett-Connor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Effects of raloxifene on lipid and lipoprotein levels in postmenopausal osteoporotic women with and without hypertriglyceridemia
Thomas Dayspring et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2006)
Epidemiology, etiology, and diagnosis of osteoporosis
NE Lane
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2006)
New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality
V Sundararajan et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2004)
Taiwan's new national health insurance program: Genesis and experience so far
TM Cheng
HEALTH AFFAIRS (2003)
Arterial and cardiac aging: Major shareholders in cardiovascular disease enterprises Part I: Aging arteries: A set up for vascular disease
EG Lakatta et al.
CIRCULATION (2003)
Osteoporosis in elderly: prevention and treatment
M Srivastava et al.
CLINICS IN GERIATRIC MEDICINE (2002)
Raloxifene and cardiovascular events in osteoporotic postmenopausal women - Four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial
E Barrett-Connor et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Characterization of perimenopausal bone loss: A prospective study
R Recker et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2000)
分享论文
